Reevaluating Patient Eligibility for Inotuzumab Ozogamicin Based on CD22 Expression: Is Dim Expression Sufficient?
| العنوان: | Reevaluating Patient Eligibility for Inotuzumab Ozogamicin Based on CD22 Expression: Is Dim Expression Sufficient? |
|---|---|
| المؤلفون: | Warren Fingrut, Chantal S. Leger, Camilla Ross, Heather A. Leitch, Eric McGinnis, Karen Dallas, Wendy W. Davis, Khaled M. Ramadan, Yasser Abou Mourad, Ryan D. Cassaday, Hayley Merkeley |
| المصدر: | Current Oncology Current Oncology, Vol 28, Iss 27, Pp 252-259 (2021) |
| بيانات النشر: | MDPI AG, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Oncology, medicine.medical_specialty, medicine.drug_class, Sialic Acid Binding Ig-like Lectin 2, Lymphoblastic Leukemia, medicine.medical_treatment, Case Report, acute lymphoblastic leukemia, Antibodies, Monoclonal, Humanized, Monoclonal antibody, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, hemic and lymphatic diseases, Internal medicine, Calicheamicin, medicine, Humans, Inotuzumab Ozogamicin, In patient, RC254-282, Inotuzumab ozogamicin, business.industry, flow cytometry, CD22, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, cd22, Immunotherapy, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Survival benefit, chemistry, 030220 oncology & carcinogenesis, Quality of Life, immunotherapy, business, 030215 immunology, medicine.drug |
| الوصف: | Salvage options for patients with relapsed B-cell acute lymphoblastic leukemia (B-ALL) include inotuzumab ozogamicin (InO), a recombinant, humanized anti-CD22 monoclonal antibody conjugated to the cytotoxic antibiotic calicheamicin. However, the benefit of InO in patients with dim CD22 expression remains unclear. We present a case of a patient with B-ALL who responded to InO despite only dim surface expression of CD22 by flow cytometry, achieving a survival benefit concordant with that reported in the literature and maintaining a good quality of life as a transfusion-independent outpatient. Our observation has broad relevance to clinicians who manage patients with B-ALL who are candidates for InO. |
| تدمد: | 1718-7729 |
| DOI: | 10.3390/curroncol28010027 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f10a9819ef06531419e655c9876d7998 https://doi.org/10.3390/curroncol28010027 |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....f10a9819ef06531419e655c9876d7998 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 17187729 |
|---|---|
| DOI: | 10.3390/curroncol28010027 |